+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Vasculitis Treatment - Global Strategic Business Report

  • PDF Icon

    Report

  • 308 Pages
  • May 2026
  • Region: Global
  • Market Glass, Inc.
  • ID: 5309834
The global market for Vasculitis Treatment was estimated at US$295.4 Million in 2025 and is projected to reach US$388.1 Million by 2032, growing at a CAGR of 4.0% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Vasculitis Treatment Market - Key Trends & Drivers Summarized

Why Is There an Increasing Focus on Vasculitis Treatment?

Vasculitis, a group of rare inflammatory diseases that cause blood vessel inflammation, has garnered increasing attention in the medical community due to its complex nature and potential for severe complications. The need for effective vasculitis treatment has grown as awareness of the disease and its varied presentations has increased. Early and accurate diagnosis is critical for managing vasculitis and preventing long-term damage to vital organs such as the kidneys, lungs, and heart. As healthcare providers and researchers work to develop more targeted and effective therapies, the demand for advanced treatment options has risen, driving growth in the vasculitis treatment market.

How Are Advances in Medicine Influencing Vasculitis Treatment?

Advances in medicine, particularly in immunology and biologic therapies, have significantly influenced the treatment of vasculitis. The development of targeted biologic drugs, such as rituximab and tocilizumab, which specifically modulate the immune response, has transformed the management of vasculitis, offering new hope to patients who do not respond to traditional therapies. Additionally, the use of advanced diagnostic tools, including imaging and molecular testing, has improved the ability to accurately diagnose and monitor vasculitis, leading to more personalized and effective treatment plans. The integration of these medical advancements into clinical practice has enhanced the ability to control disease activity, reduce relapses, and improve overall patient outcomes.

What Are the Emerging Trends in Vasculitis Treatment?

The vasculitis treatment market is witnessing several emerging trends that are shaping its development. One significant trend is the increasing use of biologic therapies, which offer a more targeted approach to treating vasculitis by modulating specific components of the immune system. Another trend is the growing focus on personalized medicine, with treatments tailored to the individual patient`s genetic and immunologic profile, leading to more effective and precise management of the disease. The market is also seeing a rise in the use of combination therapies, where biologics are used alongside traditional immunosuppressive drugs to achieve better control of disease activity. Additionally, there is an increasing emphasis on the development of novel therapeutic agents that can address unmet needs in vasculitis treatment, particularly for patients with refractory or severe disease.

What Factors Are Driving the Growth of the Vasculitis Treatment Market?

The growth in the vasculitis treatment market is driven by several factors, including the increasing prevalence and awareness of vasculitis, which has led to more frequent diagnoses and a greater need for effective treatments. The development of advanced biologic therapies, which have expanded the range of treatment options available to patients, is also a significant driver of market growth. Additionally, the growing emphasis on personalized medicine, driven by advances in genomics and molecular diagnostics, is influencing the adoption of more targeted therapies for vasculitis. The rising focus on improving patient outcomes, particularly in terms of reducing disease activity and preventing long-term complications, is further boosting demand for innovative treatment options. Moreover, the increasing investment in research and development, supported by government initiatives and collaborations between academic institutions and pharmaceutical companies, is contributing to the market`s expansion.

Report Scope

The report analyzes the Vasculitis Treatment market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:
  • Segments: Drug Class (Corticosteroids Drug Class, Immunosuppressants Drug Class, Biologics Drug Class); Disease Type (Small Vessel Vasculitis Disease Type, Medium Vessel Vasculitis Disease Type, Large Arteries Vasculitis Disease Type); Administration Route (Intramuscular & Subcutaneous Administration Route, Intradermal Administration Route, Oral Administration Route, Other Administration Routes); Distribution Channel (Hospital Pharmacies Distribution Channel, Retail Distribution Channel, Online Distribution Channel); End-Use (Hospitals End-Use, Specialty Clinics End-Use, Academic & Research Institutes End-Use, Other End-Uses)
  • Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Corticosteroids Drug Class segment, which is expected to reach US$197.6 Million by 2032 with a CAGR of a 4.9%. The Immunosuppressants Drug Class segment is also set to grow at 2.7% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $87.0 Million in 2025, and China, forecasted to grow at an impressive 3.9% CAGR to reach $69.6 Million by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Vasculitis Treatment Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Vasculitis Treatment Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Vasculitis Treatment Market expected to evolve by 2032?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2032?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as AB Science SA, Ablynx NV, Acorda Therapeutics, Inc., Antares Pharma, Inc., Astellas Pharma, Inc. and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Vasculitis Treatment market report include:

  • AB Science SA
  • Ablynx NV
  • Acorda Therapeutics, Inc.
  • Antares Pharma, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Baxter International, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Can-Fite BioPharma Ltd.
  • Celgene Corporation
  • Celltrion Healthcare Co., Ltd.
  • Coherus BioSciences
  • Daiichi Sankyo Co., Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Hospira, Inc.
  • Idera Pharmaceuticals, Inc.
  • Immunomedics, Inc.
  • Incyte Corporation
  • Lexicon Pharmaceuticals, Inc.
  • MedImmune LLC
  • Merck & Co., Inc.
  • Morphotek, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Regeneron Pharmaceuticals, Inc.
  • Sandoz International GmbH
  • Sanofi SA
  • Takeda Pharmaceutical Co., Ltd.
  • UCB SA
  • Vertex Pharmaceuticals Inc.

Domain Expert Insights

This market report incorporates insights from domain experts across enterprise, industry, academia, and government sectors. These insights are consolidated from multilingual multimedia sources, including text, voice, and image-based content, to provide comprehensive market intelligence and strategic perspectives. As part of this research study, the publisher tracks and analyzes insights from 8,223 domain experts. Clients may request access to the network of experts monitored for this report, along with the online expert insights tracker.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
  • How Trump’s Tariffs Impact the Market? The Big Question on Everyone’s Mind
  • Vasculitis Treatment - Global Key Competitors Percentage Market Share in 2026 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2026 (E)
  • Global Economic Update
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Autoimmune Disorders Driving Market Demand
  • Advancements in Biologic Therapies for Vasculitis
  • Increasing Adoption of Personalized Medicine in Vasculitis Treatment
  • Growing Demand for Immunosuppressive Drugs
  • Expansion of Clinical Trials for New Vasculitis Treatments
  • Technological Innovations in Diagnostic Tools for Vasculitis
  • Impact of Healthcare Reforms on Treatment Accessibility
  • Growing Awareness and Patient Education on Vasculitis
  • Emergence of Targeted Therapies for Specific Vasculitis Types
  • Increasing Investments in R&D for Vasculitis Therapeutics
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Vasculitis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 2: World Historic Review for Vasculitis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 3: World 13-Year Perspective for Vasculitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020, 2026 & 2032
  • Table 4: World Vasculitis Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2020 through 2032
  • Table 5: World Recent Past, Current & Future Analysis for Corticosteroids Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 6: World Historic Review for Corticosteroids Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 7: World 13-Year Perspective for Corticosteroids Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 8: World Recent Past, Current & Future Analysis for Immunosuppressants Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 9: World Historic Review for Immunosuppressants Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 10: World 13-Year Perspective for Immunosuppressants Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 11: World Recent Past, Current & Future Analysis for Biologics Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 12: World Historic Review for Biologics Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 13: World 13-Year Perspective for Biologics Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 14: World Recent Past, Current & Future Analysis for Small Vessel Vasculitis Disease Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 15: World Historic Review for Small Vessel Vasculitis Disease Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 16: World 13-Year Perspective for Small Vessel Vasculitis Disease Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 17: World Recent Past, Current & Future Analysis for Medium Vessel Vasculitis Disease Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 18: World Historic Review for Medium Vessel Vasculitis Disease Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 19: World 13-Year Perspective for Medium Vessel Vasculitis Disease Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 20: World Recent Past, Current & Future Analysis for Large Arteries Vasculitis Disease Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 21: World Historic Review for Large Arteries Vasculitis Disease Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 22: World 13-Year Perspective for Large Arteries Vasculitis Disease Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 23: World Recent Past, Current & Future Analysis for Intramuscular & Subcutaneous Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 24: World Historic Review for Intramuscular & Subcutaneous Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 25: World 13-Year Perspective for Intramuscular & Subcutaneous Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 26: World Recent Past, Current & Future Analysis for Intradermal Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 27: World Historic Review for Intradermal Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 28: World 13-Year Perspective for Intradermal Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 29: World Recent Past, Current & Future Analysis for Oral Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 30: World Historic Review for Oral Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 31: World 13-Year Perspective for Oral Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 32: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 33: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 34: World 13-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 35: World Recent Past, Current & Future Analysis for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 36: World Historic Review for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 37: World 13-Year Perspective for Hospital Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 38: World Recent Past, Current & Future Analysis for Retail Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 39: World Historic Review for Retail Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 40: World 13-Year Perspective for Retail Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 41: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 42: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 43: World 13-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 44: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 45: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 46: World 13-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 47: World Recent Past, Current & Future Analysis for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 48: World Historic Review for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 49: World 13-Year Perspective for Specialty Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 50: World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 51: World Historic Review for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 52: World 13-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • Table 53: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 54: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 55: World 13-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
III. MARKET ANALYSIS
UNITED STATES
  • Vasculitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
CANADA
JAPAN
  • Vasculitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
CHINA
  • Vasculitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
EUROPE
  • Vasculitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
FRANCE
  • Vasculitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
GERMANY
  • Vasculitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
ITALY
UNITED KINGDOM
  • Vasculitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
REST OF EUROPE
ASIA-PACIFIC
  • Vasculitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
REST OF WORLD
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AB Science SA
  • Ablynx NV
  • Acorda Therapeutics, Inc.
  • Antares Pharma, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Baxter International, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Can-Fite BioPharma Ltd.
  • Celgene Corporation
  • Celltrion Healthcare Co., Ltd.
  • Coherus BioSciences
  • Daiichi Sankyo Co., Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Hospira, Inc.
  • Idera Pharmaceuticals, Inc.
  • Immunomedics, Inc.
  • Incyte Corporation
  • Lexicon Pharmaceuticals, Inc.
  • MedImmune LLC
  • Merck & Co., Inc.
  • Morphotek, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Regeneron Pharmaceuticals, Inc.
  • Sandoz International GmbH
  • Sanofi SA
  • Takeda Pharmaceutical Co., Ltd.
  • UCB SA
  • Vertex Pharmaceuticals Inc.

Table Information